Ipsen is making good progress in reducing its reliance on the acromegaly and neuroendocrine tumour blockbuster Somatuline, according to CEO David Loew who has heralded the launches of two rare disease drugs, Bylvay and Iqirvo.
Ipsen Pleased With Iqirvo Launch And Plots More Deals
The Paris-headquartered group has been reflecting on a solid performance last year.
More from Deals
• By
Plus deals involving Relmada/Trigone, Alvotech/Xbrane, OPKO Health/Entera, iOncologi/TargImmune and more.
• By
Merck & Co., which already has an oral PCSK9 inhibitor in Phase III, licensed Hengrui’s Lipoprotein(a)-lowering small molecule HRS-5346 outside of Greater China for $200m up front.
• By
South Korea's LigaChem is kickstarting a growth and globalization drive through a potential future acquisition of UK ADC player IKSUDA.
• By
The obesity market leader is teaming up with China’s United Bio-Technology to develop a product they believe could beat Lilly’s late-stage same-class candidate retatrutide.